ViroVet NV

Proud to see that the cutting-edge PLLAV technology is also going into humans, Astrivax did an amazing job to get this done in less than 2 years, showcasing remarkable innovation and dedication!

https://www.linkedin.com/posts/eblomsma_astrivax-enters-clinical-phase-activity-7210913058708217856-ToFm?utm_source=share&utm_medium=member_desktop

Another big step for ViroVet

ViroVet scores with PRRS vaccine based on PLLAV technology LEUVEN, Belgium, March 27th, 2023 - ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, proudly announces the development of a porcine reproductive and respiratory syndrome (PRRS) vaccine based on the PLLAV (Plas

ViroVet will be presenting at Animal Health, Nutrition & Technology Innovation 6-8 March in London. Register now and meet us there!


https://hubs.ly/Q01yJrqw0

Here we go.... the A B C of growing our company

https://www.linkedin.com/pulse/virovet-completes-series-c-funding-erwin-blomsma/

News again? Yes!

https://www.linkedin.com/pulse/spectacular-results-japanese-encephalitis-vaccine-virovet-blomsma/

Spectacular results with Japanese encephalitis vaccine of ViroVet LEUVEN, Belgium, December 7th, 2021 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that its vaccine against Japanese encephalitis (JE) provides strong protection against infection. J...

BREAKING NEWS: ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV infected pigs

September 9, 2021 - Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine fever (ASF). In the absence of a vaccine, antiviral drugs will provide an alternative control method which can help limit clinical signs in pigs and lower virus replication. This will reduce the spread of disease and help to contain outbreaks, ultimately reducing the number of pigs lost to this deadly viral infection.

The research, part funded by the Biotechnology and Biological Sciences Research Council LINK programme, has led to the selection of several antiviral drugs that were already screened by ViroVet. These antivirals have shown to be potent and selective inhibitors of ASF viral replication in cells in the absence of cellular toxicity.

A first candidate drug was trialled at Pirbright’s unique high containment facilities this summer and demonstrated effectiveness in reducing ASF viral replication and disease in pigs. One third of the treated animals survived the challenge with ASF virus without significant disease signs and appeared to have cleared the virus. Further studies are planned with optimised dose regimens in the following months.

Dr Erwin Blomsma, Chief Executive Officer of ViroVet: “The recent outbreaks of ASF in Asia have caused more than 100 billion USD damage, there is a clear and urgent need for antiviral drugs as well as vaccines.”

Dr Linda Dixon, Head of the African Swine Fever Group at The Pirbright Institute, said: “This study is a very promising first step in providing an important tool for control of African swine fever that can be used alone or in combination with vaccines..”

Dr Nesya Goris, Chief Development Officer and co-founder of ViroVet added: “African swine fever is a devastating and often fatal disease. It is rewarding to be part of a team working on a potential solution.”

https://www.linkedin.com/pulse/virovet-successful-second-vaccine-based-new-rega-assesses-blomsma

ViroVet successful with second vaccine based on new vaccine technology, Rega Institute assesses development of human version | by Erwin Blomsma | LinkedIn Published: March 22, 2021. LEUVEN, Belgium, March 22nd, 2021 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has successfully constructed a vaccine against Japanese encephalit...

eerder dit jaar werkten we even mee aan het coronavaccin van KU Leuven, fijn om te zien dat het vaccin goed lijkt te werken!

https://twitter.com/KU_Leuven/status/1333763947112050689?s=20

KU Leuven on Twitter “Today, researchers at the KU Leuven lab published the results of their preclinical study into a Covid-19 vaccine candidate in . The vaccine also works against yellow fever. ➡️ The paper: https://t.co/evzqoB0rxC ➡️ Our story: https://t.co/aB92azfEGo”

https://www.linkedin.com/pulse/first-vaccine-based-virovet-pllav-technology-enters-erwin-blomsma/

First vaccine based on ViroVet PLLAV technology enters development LEUVEN, Belgium, October 21st, 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has successfully confirmed the efficacy of its porcine reproductive and respiratory syndrom...

Learn more about "probably the best SARS-CoV-2 vaccine candidate in the world" and how ViroVet was involved
https://www.biorxiv.org/content/10.1101/2020.07.08.193045v1

A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines to quench the unrestrained spread of SARS-CoV-2. Several promising vaccine platforms, developed in recent years, are leveraged for a rapid emergency response to COVID-19. We employed the l...

Vaccine technology delivers promising candidate vaccine

https://twitter.com/virovet/status/1281251141813178368?s=20

virovet on Twitter “Check out the latest news: KU Leuven virologists select SARS-CoV-2 coronavirus vaccine candidate for clinical trials https://t.co/hbkLQeU52s via ”

https://www.linkedin.com/pulse/seventure-partners-joins-virovet-series-b-funding-erwin-blomsma/

Seventure Partners joins ViroVet in series B funding LEUVEN, Belgium, May 28th, 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has successfully concluded the first closing of its series B financing round, raising over 6 mi...

ViroVet at the frontline, the corona team meets

https://www.linkedin.com/pulse/virovet-support-covid19-research-sample-testing-erwin-blomsma/

ViroVet to support COVID19 research and sample testing Belgian biotechnology company ViroVet announced today that it has made its expertise, research staff as well as part of its research facility available to support COVID19 research and sample testing in Belgium. According to its CEO, Dr Erwin Blomsma, the company has a clear moral obligation to diver

Nice

https://twitter.com/virovet/status/1235124907941523456

virovet on Twitter “Last week in London, our CEO showed the power of our disruptive BVD antiviral... morbidity down by >50% and 25% less mortality ”

One more day...

https://twitter.com/virovet/status/1231217114914152448?s=21

virovet on Twitter “science or fiction? Find out what our products can do, we present results for the first time on Feb 25th 3.45pm in London ”

6 weeks from now, you will be able to learn more about ViroVet and for the first time we will share some of the spectacular results obtained in treating and preventing viral diseases in livestock more about the event here https://animalhealthevent.com/events/ah-europe-2020

10 Leuven-based startups to watch out for in 2020 | EU-Startups Belgium-Startups 10 Leuven-based startups to watch out for in 2020 By Bojana Trajkovska - December 30, 2019 Share on Facebook Tweet on Twitter The old Burgundian town of Leuven is the most famous university city in Belgium. It is the home of 600 year-old ‘KU Leuven’, ranked by Reuters as the mos...

ViroVet NV updated their phone number.

ViroVet NV updated their website address.

The ViroVet team wishes you a very happy holiday season and a wonderful 2020!

Our African swine fever experts are joining forces with ViroVet NV to develop against the deadly pig disease http://ow.ly/yKwZ50urFKz BBSRC

ViroVet and Pirbright join forces to develop African swine fever antivirals

https://www.linkedin.com/pulse/virovet-pirbright-join-forces-develop-african-swine-fever-blomsma/

ViroVet and Pirbright join forces to develop African swine fever antivirals Belgian biotechnology company ViroVet will partner with Researchers at The Pirbright Institute to develop the first antiviral drugs that act against African swine fever (ASF). In the absence of a vaccine, antiviral drugs could provide an alternative control method which would help limit clinical sig

we updated our website!
www.virovet.com

ViroVet Livestock Solutions Antiviral drugs and thermostable vaccines for livestock

Enjoy the holidays, c u in 2019!

Wishing you happy holidays and a great 2019! 2018 was a nice year for us at ViroVet, enough challenges to keep us sharp, enough successes to keep us happy and loads of ambitions that we take into 2019! “I am fond of pigs. Dogs look up to us.

https://www.pigprogress.net/Health/Articles/2018/11/This-idea-could-help-gain-control-over-ASF-352408E/

This idea could help gain control over ASF Almost concurrent with the first reported African Swine Fever (ASF) outbreaks in Belgium, a Belgian startup delivered a pitch for a disruptive technology to take control of ASF outbreaks at the first Foodbytes event in London, United Kingdom, in September.

https://agfundernews.com/agrifood-tech-startup-spotlight-europes-virovet-is-developing-novel-livestock-vaccines.html/

AgriFood Tech Startup Spotlight: Europe’s ViroVet is Developing Novel Livestock Vaccines - AgFunderNews This week we spoke with Belgian animal health startup ViroVet to learn more about its mission to tackle health and wellness in the livestock industry with novel vaccine and antibiotic reduction technology.

https://www.linkedin.com/pulse/virovet-being-watched-closely-erwin-blomsma/

ViroVet is being watched closely names us a Ones to Watch – one of a select group of 60 up-and-coming companies. The Ones to Watch list, a sister list to the Global Cleantech 100, showcases up-and-coming companies that represent segments and sectors more people in the market should pay attention to.

Look what we found on 2dehands.be: a reception desk for our BioHub, next step will be to find a new team member!

https://www.linkedin.com/pulse/what-difference-10-years-makes-erwin-blomsma/

what a difference 10 years makes October 17, 2018 - The article below was produced by KU Leuven Research and Development some years ago, we repeat it here to celebrate the 10th anniversary of VC funding of one of the world's first animal health biotech companies, Okapi Sciences. The team that built Okapi Sciences is now building an